A Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN) -Associated Myelofibrosis and Anemia

Trial Profile

A Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN) -Associated Myelofibrosis and Anemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Sotatercept (Primary) ; Ruxolitinib
  • Indications Anaemia; Myelofibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Jan 2018 Planned End Date changed from 1 Feb 2019 to 1 Feb 2020.
    • 05 Jan 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.
    • 12 Dec 2017 Updated results from the sotatercept monotherapy cohort (n=24) and the first results from the combination cohort (n=9) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top